MedTrace Logo

CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT05146336 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-09-11

No results posted yet for this study

Summary

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Conditions

  • Septic Shock
  • Acute Respiratory Distress Syndrome
  • Trauma
  • Rhabdomyolysis
  • Cardiogenic Shock
  • Pancreatitis
  • Acute on Chronic Liver Failure
  • Acute Liver Failure
  • Burns
  • Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)
  • Extracorporeal Life Support
  • Postoperative Endocarditis
  • Hemophagocytic Lymphohistiocytoses
  • Liver Transplant; Complications
  • Infectious Disease
  • Postoperative Vasoplegic Syndrome
  • Drug Overdose
  • Sepsis

Interventions

DEVICE

CytoSorb

Sorbent hemoperfusion system

Sponsors & Collaborators

  • CytoSorbents, Inc

    lead INDUSTRY

Principal Investigators

  • Ricard Ferrer Roca, MD · Hospital Vall d'Hebron

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2032-06-30
Completion
2032-09-30

Countries

  • Austria
  • Germany
  • Italy
  • Poland
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05146336 on ClinicalTrials.gov